|
Status
|
Awaiting development
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
STA Standard
|
| ID number |
6288
|
Provisional Schedule
| Committee meeting |
04 August 2024 |
| Expected publication |
13 November 2024 |
Project Team
| Project lead |
Celia.Mayers@nice.org.uk |
Email enquiries
Stakeholders
| Companies sponsors |
Eli Lilly (selpercatinib) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Association for Multiple Endocrine Neoplasia Disorders (AMEND) |
| |
Butterfly Thyroid Cancer Trust |
| Professional groups |
Association of Cancer Physicians |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| Comparator companies |
None |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
| |
Welsh Government |
| Relevant research groups |
Institute of Cancer Research |
|
Date
|
Update
|
|
05 February 2024
|
Invitation to participate |
|
05 December 2023 - 16 January 2024
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
|
05 December 2023
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
|
05 December 2023
|
NICE will be undertaking a guidance update for [TA742] Selpercatinib for treating advanced thyroid cancer with RET alterations which recommended the use of Selpercatinib in the Cancer Drugs Fund while further data were collected. The aim of the update is to decide whether or not the drug can be recommended for routine use after data collection is complete.
Please see draft timelines we have planned for your information. Following conversations with the company the appraisal is expected to start in approximately early December 2023 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an Invitation to Participate in the appraisal during early February 2024 when we will write to you about how you can get involved. |
For further information on our processes and methods, please see our CHTE processes and methods manual